FR17C1024I2 - Polypeptide de facteur viii - Google Patents

Polypeptide de facteur viii

Info

Publication number
FR17C1024I2
FR17C1024I2 FR17C1024C FR17C1024C FR17C1024I2 FR 17C1024 I2 FR17C1024 I2 FR 17C1024I2 FR 17C1024 C FR17C1024 C FR 17C1024C FR 17C1024 C FR17C1024 C FR 17C1024C FR 17C1024 I2 FR17C1024 I2 FR 17C1024I2
Authority
FR
France
Prior art keywords
factor viii
viii polypeptide
polypeptide
factor
viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1024C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Chemicals Co Ltd
Original Assignee
SK Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Chemicals Co Ltd filed Critical SK Chemicals Co Ltd
Publication of FR17C1024I1 publication Critical patent/FR17C1024I1/fr
Application granted granted Critical
Publication of FR17C1024I2 publication Critical patent/FR17C1024I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR17C1024C 2003-01-28 2017-07-03 Polypeptide de facteur viii Active FR17C1024I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/353,753 US7041635B2 (en) 2003-01-28 2003-01-28 Factor VIII polypeptide
PCT/KR2003/002277 WO2004067566A1 (en) 2003-01-28 2003-10-27 Factor viii polypeptide

Publications (2)

Publication Number Publication Date
FR17C1024I1 FR17C1024I1 (OSRAM) 2017-09-08
FR17C1024I2 true FR17C1024I2 (fr) 2019-07-19

Family

ID=32736253

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1024C Active FR17C1024I2 (fr) 2003-01-28 2017-07-03 Polypeptide de facteur viii

Country Status (13)

Country Link
US (1) US7041635B2 (OSRAM)
EP (2) EP1587832B1 (OSRAM)
KR (1) KR100642293B1 (OSRAM)
CN (1) CN100404552C (OSRAM)
AU (1) AU2003274766B8 (OSRAM)
BE (1) BE2017C021I2 (OSRAM)
CA (1) CA2514646C (OSRAM)
DK (2) DK1587832T3 (OSRAM)
ES (1) ES2446041T3 (OSRAM)
FR (1) FR17C1024I2 (OSRAM)
LU (1) LUC00023I2 (OSRAM)
NL (1) NL300878I2 (OSRAM)
WO (1) WO2004067566A1 (OSRAM)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296768B2 (en) * 2003-12-03 2010-06-24 University Of Rochester Recombinant factor VIII having increased specific activity
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1874815A1 (en) * 2005-04-14 2008-01-09 CSL Behring GmbH Modified coagulation factor viii with enhanced stability and its derivates
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007065691A2 (en) 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
AU2007269233B2 (en) * 2006-06-30 2011-06-09 Cnj Holdings, Inc. Method of producing Factor VIII proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
LT2126106T (lt) 2007-02-23 2018-01-10 Sk Chemicals Co., Ltd. Viii faktoriaus ir jo darinių gavimo ir gryninimo būdas
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
EP2209908B1 (en) * 2007-11-01 2014-09-03 University Of Rochester Recombinant factor viii having increased stability
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
US20110077202A1 (en) * 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
NZ606427A (en) 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
EP2482841B2 (en) 2009-10-02 2022-09-28 The Children's Hospital Of Philadelphia Compositions and methods for enhancing coagulation factor viii function
JP5903048B2 (ja) 2009-12-06 2016-04-13 バイオジェン ヘモフィリア インコーポレイテッド 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
CN103298483B (zh) 2010-11-05 2017-04-12 百深有限责任公司 具有增加的比活性的抗血友病因子viii的新型变体
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
TWI687226B (zh) 2011-07-08 2020-03-11 美商百歐維拉提夫治療公司 因子ｖｉｉｉ嵌合及雜交多肽，及其使用方法
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9511123B2 (en) 2011-10-18 2016-12-06 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
ES2600081T3 (es) 2011-10-18 2017-02-07 Csl Behring Gmbh Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII
KR20140084208A (ko) * 2011-10-18 2014-07-04 시에스엘 리미티드 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
EP3970737A1 (en) 2012-01-12 2022-03-23 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
ES2935489T3 (es) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
KR101395736B1 (ko) * 2012-07-10 2014-05-16 아주대학교산학협력단 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
NZ703366A (en) 2012-07-11 2018-03-23 Amunix Operating Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
RS64664B1 (sr) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
EP3666283B1 (en) 2013-03-15 2022-06-08 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
TWI788044B (zh) 2013-03-15 2022-12-21 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
KR20230007555A (ko) 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EP4332839A3 (en) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
PL3091997T3 (pl) 2014-01-10 2023-01-02 Bioverativ Therapeutics Inc. Białka chimeryczne czynnika viii i ich zastosowania
KR101908074B1 (ko) * 2014-01-20 2018-10-15 옥타파마 아게 개선된 FVIII:C/FVIII:Ag의 비를 갖는 인자 VIII의 제조방법
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EP3177317B1 (en) 2014-08-04 2020-03-18 CSL Limited Factor viii formulation
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CN107810194B (zh) 2015-05-22 2021-10-08 康诺贝林伦瑙有限公司 用于制备经修饰的血管性血友病因子的方法
CN107787328B (zh) 2015-05-22 2021-08-06 康诺贝林伦瑙有限公司 用于治疗血友病的截短的血管性血友病因子多肽
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
WO2017050820A1 (en) * 2015-09-22 2017-03-30 Novo Nordisk A/S Fviii fusion proteins
CN108884145B (zh) 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
IL259295B2 (en) 2015-11-13 2024-10-01 Baxalta Inc Viral vectors encoding recombinant FVIII variants with enhanced expression for gene therapy in hemophilia A
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
PH12018501628B1 (en) 2016-02-01 2023-11-10 Bioverativ Therapeutics Inc Optimized factor viii genes
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
KR102219859B1 (ko) 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
JP6351679B2 (ja) * 2016-09-30 2018-07-04 エスケー ケミカルズ カンパニー リミテッド 第ｖｉｉｉ因子とその誘導体の製造及び精製方法
CA3043397A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
WO2018234518A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
JP2021512126A (ja) 2018-02-01 2021-05-13 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子を発現するレンチウイルスベクターの使用
JP7534219B2 (ja) 2018-04-04 2024-08-14 シギロン セラピューティクス， インコーポレイテッド 移植可能な粒子及び関連方法
DK3793588T3 (da) 2018-05-18 2025-06-16 Bioverativ Therapeutics Inc Fremgangsmåder til behandling af hæmofili a
EP3823985A1 (en) 2018-07-16 2021-05-26 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
EP3833766A1 (en) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
WO2020061281A1 (en) * 2018-09-19 2020-03-26 Cell Machines, Inc. Methods and compositions related to improved factor viii long half-life coagulation complexes
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
MA54951A (fr) * 2019-02-15 2021-12-22 Bayer Healthcare Llc Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
CN114127501B (zh) 2019-03-14 2023-02-17 泰尔茂比司特生物技术有限公司 多部分冻干容器及使用方法
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
KR20220022110A (ko) * 2019-06-05 2022-02-24 크리스퍼 테라퓨틱스 아게 개선된 인자 viii 발현을 사용한, a형 혈우병을 위한 유전자 편집
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
US20230023826A1 (en) 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP7681268B2 (ja) 2020-03-30 2025-05-22 シスメックス株式会社 血液凝固活性の測定方法
IL299333A (en) 2020-06-24 2023-02-01 Bioverativ Therapeutics Inc Methods for the purification of viral vectors
US20240269241A1 (en) 2021-06-14 2024-08-15 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
AU2022332276A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
JP2025534659A (ja) 2022-10-11 2025-10-17 シギロン セラピューティクス， インコーポレイテッド 疾患治療のための改変細胞及び移植可能エレメント
TW202517669A (zh) 2023-07-05 2025-05-01 日商武田藥品工業股份有限公司 用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
AU670793B2 (en) * 1992-04-30 1996-08-01 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor VIII complex
WO1997040145A1 (en) 1996-04-24 1997-10-30 The Regents Of The University Of Michigan Inactivation resistant factor viii
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
EP1397496A2 (en) 2001-06-15 2004-03-17 Andre Schuh Gene therapy for hemophilia a

Also Published As

Publication number Publication date
BE2017C021I2 (OSRAM) 2023-03-07
US20040147436A1 (en) 2004-07-29
EP2253645A2 (en) 2010-11-24
CN1745100A (zh) 2006-03-08
AU2003274766A1 (en) 2004-08-23
CA2514646A1 (en) 2004-08-12
CN100404552C (zh) 2008-07-23
NL300878I2 (nl) 2017-11-02
US7041635B2 (en) 2006-05-09
LUC00023I2 (OSRAM) 2017-09-08
EP1587832B1 (en) 2013-12-11
FR17C1024I1 (OSRAM) 2017-09-08
KR20050044776A (ko) 2005-05-12
AU2003274766B2 (en) 2009-02-12
EP2253645A3 (en) 2011-02-16
ES2446041T3 (es) 2014-03-06
EP1587832A1 (en) 2005-10-26
AU2003274766B8 (en) 2009-08-27
DK2253645T3 (en) 2016-06-27
LUC00023I1 (OSRAM) 2017-06-21
KR100642293B1 (ko) 2006-11-03
WO2004067566A1 (en) 2004-08-12
EP2253645B1 (en) 2016-03-23
DK1587832T3 (en) 2014-02-24
CA2514646C (en) 2013-07-23
HK1150840A1 (en) 2012-01-13

Similar Documents

Publication Publication Date Title
FR17C1024I2 (fr) Polypeptide de facteur viii
NO2014013I2 (no) Linaclotide
ATE389374T1 (de) Zwischenwirbelimplantat
DE50310628D1 (de) Erfahren
DK1752470T3 (da) GAG-bindende proteiner
DE50308359D1 (de) Armlehne
DE50308343D1 (de) Armlehne
DK1490404T3 (da) Laktoferrin
SE0303324L (sv) Implantat
DE50302584D1 (de) Stereomikroskop
DE50302514D1 (de) Stereomikroskop
ATE542105T1 (de) Sprengreihenfolgensteuerung
DK1664096T3 (da) Antimikrobielle peptider
DK1664095T3 (da) Antimikrobielle polypeptider
DE602004027594D1 (de) Triac
FR2861758B1 (fr) Element de caniveau
SE0303322L (sv) Implantat
DE60322439D1 (de) Anschlussstück
DK1625148T3 (da) Peptidkompleks
DE112004002369D2 (de) Belag
DE602004007823D1 (de) Steuer-anordnung
DE60320433D1 (de) Rückspiegelanordnung
DE602004012316D1 (de) Schaltanordnung
NO20050436D0 (no) Beta-lagnedbrytende peptider
NO20053512D0 (no) IL-8-liknende proteiner